PepMix™ Peptide Pools
Overlapping peptide pools (peptide mixes of overlapping peptide scans from virus or tumor antigens such as CMV peptide pools, HPV peptide pools or HIV peptide pools) or mixed antigenic peptide pools (e.g. CEF Pool with antigens from CMV, EBV and Influenza) are extremely efficient for antigen-specific T-cell stimulation in T cell assays, T-cell expansion, immune monitoring, cellular immune response profiling or T-cell epitope identification.
In addition to overlapping peptide pools that covers entire antigens, we offer selected antigen peptide pools such as CEF Pool, EF Pool and CEFT Pools. Peptide Pools can also be used to standardize T-cell assays, as synthetic pooled peptides are much more robust and reliable for T-cell stimulation (e.g. in ELISPOT, ICS, cytotoxity or proliferation assays) than proteins or lysates.
Control Peptide Pools for T-cell Assays
PepMix™ Collections for Immune Response Qualification
Peptide Pools for Infectious Diseases Antigens
Peptide Pools for Tumor Associated Antigens
Custom Peptide Pools & Matrix Pools
Custom PepMixes™ Peptide Pools
You need a specific antigen, a set of neo epitopes or a specialized peptide pool layout?
We are happy to discuss your specifications and provide your tailored PepMix™, neo epitope pools or matrix pools. Our customer support team will assist you with peptide scans, sequence and pool design. Subsequently, we will chemically synthesize, purify and analyze the peptides in compliance with the requirements of T-cell assays. All peptide synthesis steps are optimized to avoid contaminations and failure sequences which may lead to false positive T-cell responses or inhibition of T-cell responses.
Pooling and aliquotation are performed using our validated protocols to ensure high quality purified pooled peptides in freeze dried aliquots for long stability.
Custom PepMix™ Production
Applications for PepMix™ Peptide Pools
- Antigen-specific stimulation of T-cells
- Immune monitoring during diseases or therapy
- Assessment of vaccine efficacy
- T-cell expansion
- T-cell epitope identification
- Cellular immune response profiling
- Evaluation of neo epitopes
- Identification of the best antigen for individual patients (PepMix™ Collections)
"Developing Multi-HIV Antigen Specific T-Cells as a Component of a Cure Strategy"
by Sharon Lam, Conras Russell Cruz and Catherine Bollard
"Cytomegalovirus Protein Spanning PepMix™ Peptide Pools to Discover Changes in T cell immunity in the Aging Population"
by F. Kern, Brighton and Sussex Medical School, UK
"T cell Therapy for Viral Infections After Hematopoietic Stem Cell Transplant"
by A. M. Leen, Baylor College of Medicine TX, USA
"Qualification and Use of Peptide Libraries for Clinical Trial Immunomonitoring"
by Josephine H Cox & Peter Hayes, The International AIDS Vaccine Initiative, London, GB
Benefits of PepMix™ Peptide Pools
Overlapping peptide pools are preferable to whole proteins for antigen-specific T-cell stimulation because:
- Equivalent or better stimulation of CD4 and CD8 cells
- More reliable as control than phytohemagglutinin (PHA) and concanavalin A (ConA)
- Improved responses in stored blood and PBM cells
- High-batch-to-batch reproducibility
- Reliable chemical and biochemical quality control and quality assurance for peptide synthesis and peptide pool generation
- Prolonged shelf stability when stored freeze dried
Testimonials for PepMix™ Peptide Pools
"To establish a novel role for myeloid derived suppressor cells (Pallett et al, Nat. Med. 2015) in chronic viral infection, we utilised the PepMix CEF Pool (extended) as well as a custom synthesized PepMix spanning the core region of HBV genotype D . Whereas, the CEF peptide pool consists of 32 peptides, each corresponding to a defined HLA class I-restricted T-cell epitope from Cytomegalo, Epstein-Barr, and Influenza virus, the latter custom PepMix included 15meric peptides overlapping by 10 amino acids. Specifically this composition enabled us to monitor both the antiviral CD8+ and CD4+ T cell responses in chronic HBV infection and the non-antigen specific T cells that are known to mediate immunopathology in the liver. Our entire experience with JPT, from ordering/delivery to use in the lab was excellent. Not only were the reagents able to perform reliably and consistently in vitro from batch to batch, the customer and technical support provided was continually available and efficient when needed. JPT will remain our "go-to" company for purchasing peptides."
Dr Laura J Pallett, Infection and Immunity, University College London, UK.
"The main focus of my research group at the Charité in Berlin is the development of novel immunotherapeutic approaches against cancer and infectious diseases. For reliable monitoring of tumor and virus specific T-cell responses, we have a permanent need for peptide synthesis and peptide pools that are produced in a regulated environment for application in a clinical environment. JPT has been a long term and dedicated partner in this regard, which continuously works on improving it's peptide based services."
Prof. Dr. Carmen Scheibenbogen, Charité Berlin, Germany
Selected References for PepMix™ Peptide Pools
Combined PI3K/Akt and Hsp90 Targeting Synergistically Suppresses Essential Functions of Alloreactive T Cells and Increases Tregs Berges et al., J. Leukoc. Biol. (2015) - PMID: 26265781
K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo
Caruana et al., Clin Cancer Res. (2015) - PMID: 25691731
Development of a Novel IGRA Assay to Test T Cell Responsiveness to HBV Antigens in Whole Blood of Chronic Hepatitis B Patients
Dammermann et al., J Transl Med. (2015) - PMID: 25968473
Profiling T Cell Activation Using Single-Molecule Fluorescence In Situ Hybridization and Flow Cytometry
Bushkin et al., J. Immunol. (2015) - PMID: 25505292
Guidelines For the Automated Evaluation of Elispot Assays
Janetzki et al., Nature Protocols (2015) - PMID: 26110715
Self-adjuvanted mRNA Vaccination in Advanced Prostate Cancer Patients: a First-in-Man Phase I/IIa Study
Kübler et al., J Immunother Cancer. (2015) - PMID: 26082837
Characteristics of Immune Memory 10–15 years After Primary Hepatitis B Vaccination
Hummel et al., Vaccine (2015) - PMID: n.a.
A Novel Lipid Nanoparticle Adjuvant Significantly Enhances B Cell and T Cell Responses to Sub-unit Vaccine Antigens
Swaminathan et al., Vaccine (2015) - PMID: 26555351
An Immunoinformatic Approach for Identification of Trypanosoma cruzi HLA-A2-Restricted CD8+ T cell Epitopes
Eickhoff et al., Hum Vaccin Immunother. (2015) - PMID: 26107442
Innate Immune Activity Correlates with CD4 T Cell-associated HIV-1 DNA Decline During Latency-Reversing Treatment with Panobinostat
Olesen et al., Journal of Virology (2015) - PMID: 26223643
High-density Preculture of PBMCs Restores Defective Sensitivity of Circulating CD8 T Cells to Virus- and Tumor-derived Antigens
Wegner et al., Blood (2015) - PMID: 26024876
Metabolic Regulation of Hepatitis B Immunopathology by Myeloid-derived Suppressor Cells
Pallett et al., Nature Medicine (2015) - PMID: 25962123
Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase Iia Randomized Clinical Trial
Munseri et al., PloSOne (2015) - PMID: 25875843
Tumor Associated Antigens:
Survivin-specific CD4+ T Cells are Decreased in Patients with Survivin-positive Myeloma
Locke et al., J Immunother Cancer (2015) - PMID: 25992291
Presence of Circulating Her-2-reactive CD8 + T-Cells is Associated with Lower Frequencies of Myeloid-derived Suppressor Cells and Regulatory T Cells, and Better Survival in Elderly Breast Cancer Patients
Kini Bailur et al., Breast Cancer Research (2015) - PMID: n.a.
Peptide Libraries for the Comprehensive Coverage of the Tumor Mutanome for Immune Monitoring and Immuno Therapy
von Hoegen et al., Journal for ImmunoTherapy of Cancer (2015)- PMID: n.a.
An HPV-E6/E7 Immunotherapy Plus PD-1 Checkpoint Inhibition Results in Tumor Regression and Reduction in PD-L1 Expression
Rice et al., Cancer Gene Therapy (2015) - PMID: 26337747
A Phase I Trial Combining Decitabine/dendritic Cell Vaccine Targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for Children with Relapsed or Therapy-Refractory Neuroblastoma and Sarcoma
Krishnadas et al., Cancer Immunol Immunother. (2015) - PMID: 26105625
STAT3 Signaling Contributes to the High Effector Activities of Interleukin-15-derived Dendritic Cells
Okada et al., Immunol Cell Biol. (2015) - PMID: 25582338
- Improve Your ELISPOT Assay
Visit our ELISPOT Workshops in Huddinge, Berlin, Montreal or Baltimore
New PepMixes™ now available!
HBV ULTRA (Capsid Protein)
HHV2 (E3 ICP0), (R1/UL39), (gD)
RLCV (EBNA1), (BZLF1)
CyCMV (TP-UL83), (GP-UL55)
--> Read more news